Andrew J. Armstrong

Also affiliated with Cornell University, Peter MacCallum Cancer Centre, Prostate Cancer Foundation, Duke Medical Center, Duke Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer

(2023)10.1158/1078-0432.c.6530555

Top 100%

0DataRank

Top 100%0 citations

Wei Fu, Hao Wang, Jong C. Park, Theodore L. DeWeese, Phuoc T. Tran +14 more

Papers

Driven by 52 papers — median percentile 0. Top paper: “Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry”.

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry

Prostate Cancer and Prostatic Diseases(2020)10.1038/s41391-020-0213-7

N/A

4.8DataRank · unranked

145 citations

Andrew J. Armstrong, Chiledum Ahaghotu, David G. McLeod, Matthew R. Cooperberg, David F. Penson +17 more

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

Investigational New Drugs(2024)10.1007/s10637-023-01410-2

N/A

1.3DataRank · unranked

67 citations

Ravit Geva, Hyun Cheol Chung, Charlotte Lemech, Wilson H. Miller, Aaron R. Hansen +12 more

Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4476

N/A

0.631DataRank · unranked

66 citations

Wei Fu, Hao Wang, Jong C. Park, Theodore L. DeWeese, Phuoc T. Tran +14 more

The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1090

N/A

0.589DataRank · unranked

10 citations

Karim Fizazi, Fred Saad, Kim N. Chi, Mary-Ellen Taplin, Cora N. Sternberg +5 more

AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients

Nature Communications(2024)10.1038/s41467-024-54847-1

N/A

0.571DataRank · unranked

21 citations

Bin Luo, Anna Kobilka, J. Lyman, Siyuan Guo, Sarah A. Munro +11 more

Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3471

N/A

0.546DataRank · unranked

37 citations

Susan Halabi, Joseph D. Schonhoft, Qian Yang, Jun Luo, David M. Nanus +19 more

A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer

Journal of Clinical Investigation(2022)10.1172/jci161858

N/A

0.529DataRank · unranked

33 citations

Jamie M. Sperger, Jennifer L. Schehr, Rana R. McKay, Hamid Emamekhoo, Anupama Singh +34 more

Rewiring of the N-Glycome with prostate cancer progression and therapy resistance

npj Precision Oncology(2023)10.1038/s41698-023-00363-2

N/A

0.470DataRank · unranked

22 citations

Colin T. McDowell, Qing Yang, Yiping He, Yue Zhao, J. Spencer Hauck +7 more

Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1

JU Open Plus(2024)10.1097/ju9.0000000000000137

N/A

0.457DataRank · unranked

8 citations

Alan H. Bryce, Maha Hussain, Neeraj Agarwal, Himisha Beltran, Matthew R. Cooperberg +33 more

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma

Cancers(2022)10.3390/cancers14153830

N/A

0.442DataRank · unranked

18 citations

Matthew D. Tucker, Landon C. Brown, Hesham Yasin, Kristin Kathleen Ancell, Andrew J. Armstrong +12 more

High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes

Cancer Discovery(2025)10.1158/2159-8290.cd-24-1509

N/A

0.425DataRank · unranked

16 citations

Jamie M. Sperger, Amy K. Taylor, Katharine E. Tippins, Shannon R. Reese, V. Carreño +31 more

The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3017

N/A

0.406DataRank · unranked

14 citations

Siyuan Guo, Joseph J. Park, David M. Nanus, Daniel J. George, Emmanuel S. Antonarakis +8 more

An autologous humanized patient-derived xenograft (PDX) model for evaluation of nivolumab immunotherapy in renal cell cancer: a case report

Stem Cell Investigation(2022)10.21037/sci-2022-029

N/A

0.345DataRank · unranked

9 citations

Andrew J. Armstrong, David S. Hsu, Yubin Kang

IMPA1-derived inositol maintains stemness in castration-resistant prostate cancer via IMPDH2 activation

The Journal of Experimental Medicine(2024)10.1084/jem.20231832

N/A

0.304DataRank · unranked

6 citations

Guihua Wang, Chien‐Feng Li, Xian Zhang, Zhen Cai, Tingjin Chen +16 more

Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer

European Urology(2025)10.1016/j.eururo.2025.07.011

N/A

0.292DataRank · unranked

6 citations

Siyuan Guo, Bin Luo, Chenxi Yu, Todd P. Knutson, Anna Kobilka +13 more

Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy

JCI Insight(2025)10.1172/jci.insight.185963

N/A

0.269DataRank · unranked

5 citations

Eda K. Holl, Yuan Wu, Anika Agarwal, Mark D. Starr, M. Martinez +7 more

ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients

European Urology(2026)10.1016/j.eururo.2025.12.021

N/A

0.241DataRank · unranked

4 citations

Daniel P. Petrylak, Neal D. Shore, Russell Z. Szmulewitz, Jeffrey Holzbeierlein, Arnauld Villers +11 more

Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab

Prostate Cancer and Prostatic Diseases(2024)10.1038/s41391-024-00794-3

N/A

0.208DataRank · unranked

3 citations

Yingmiao Liu, Qian Yang, Bin Luo, Mark D. Starr, John C. Brady +7 more

Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2

JU Open Plus(2024)10.1097/ju9.0000000000000138

N/A

0.208DataRank · unranked

3 citations

E. David Crawford, Neeraj Agarwal, Maha Hussain, Himisha Beltran, Matthew R. Cooperberg +33 more

Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.183

N/A

0.165DataRank · unranked

2 citations

Susan Halabi, Joseph D. Schonhoft, Jun Luo, David M. Nanus, Paraskevi Giannakakou +13 more

Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma (mRCC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4527

N/A

0.165DataRank · unranked

2 citations

Matthew D. Tucker, Landon C. Brown, Hesham Yasin, Kristin Kathleen Ancell, Andrew J. Armstrong +12 more

External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

Journal of Clinical Oncology(2023)10.1200/jco.22.02661

N/A

0DataRank · unranked

29 citations

Qian Yang, Akash Roy, Bin Luo, John C. Araujo, Christopher J. Logothetis +15 more

PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3233

N/A

0DataRank · unranked

25 citations

Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore +8 more

The Value of Phenotypic Precision Medicine in Prostate Cancer

The Oncologist(2022)10.1093/oncolo/oyac198

N/A

0DataRank · unranked

10 citations

Amanda J. Broderick, Daniel J. George, Oliver Sartor, Andrew J. Armstrong, Nathan Hawkey

Oncofetal protein glypican‐3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer

The Journal of Pathology(2023)10.1002/path.6063

N/A

0DataRank · unranked

19 citations

Lingfan Xu, Yinglu Zhou, Qing Cheng, J. Spencer Hauck, Yiping He +10 more

A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer

Frontiers in Molecular Biosciences(2023)10.3389/fmolb.2023.1104505

N/A

0DataRank · unranked

9 citations

Beatrice C. Thomas, Pelumi Olawuni, Maya U. Sheth, Nathan Hawkey, M. Yeshwanth +7 more

Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.247

N/A

0DataRank · unranked

1 citations

Jamie M. Sperger, Marina N. Sharifi, Yue Shi, Charlotte N. Stahlfeld, Jennifer L. Schehr +9 more

Data from Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer

(2023)10.1158/1078-0432.c.6530555

Top 100%

0DataRank

Top 100%0 citations

Wei Fu, Hao Wang, Jong C. Park, Theodore L. DeWeese, Phuoc T. Tran +14 more

Data from Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide

(2023)10.1158/1078-0432.c.6530474.v1

N/A

0DataRank · unranked

0 citations

Susan Halabi, Joseph D. Schonhoft, Qian Yang, Jun Luo, David M. Nanus +19 more

File S1 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

(2023)10.1158/1541-7786.22527275

Top 100%

0DataRank

Top 100%0 citations

Susan Halabi, Gábor Kemény, Monika Anand, Paraskevi Giannakakou, David M. Nanus +4 more

Molecular Mechanisms of Castrate-Resistant Prostate Cancer

Urologic Clinics of North America(2022)10.1016/j.ucl.2022.07.005

N/A

0DataRank · unranked

8 citations

Andrew J. Armstrong, Thomas J. Polascik, Judd W. Moul, Srinath Kotamarti

Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis

Biosensors and Bioelectronics(2022)10.1016/j.bios.2022.114445

N/A

0DataRank · unranked

34 citations

Woo‐Jin Jeong, Roya Jafari, Luke J. Kubiatowicz, Ashita Nair, Michael J. Poellmann +15 more

Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0803

N/A

0DataRank · unranked

10 citations

Olivia Bobek, Irenaeus C.C. Chan, Brian C. Miller, David W. Hillman, Glenn Heller +8 more

Liquid-biopsy transcriptomic profiling uncovers molecular mediators of resistance to androgen receptor signaling inhibition in lethal prostate cancer

medRxiv(2021)10.1101/2021.11.01.21265757

N/A

0DataRank · unranked

2 citations

Bob Zimmermann, Giuseppe Galletti, Susan Halabi, Ada Gjyrezi, Qian Yang +16 more

Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T

Cancer Research Communications(2024)10.1158/2767-9764.crc-24-0439

N/A

0DataRank · unranked

7 citations

Vincent M. D’Anniballe, David Boczkowski, Harini Kandadi, Nadeem A. Sheikh, William Kornahrens +10 more

Evaluation of ChatGPT as a Reliable Source of Medical Information on Prostate Cancer for Patients: Global Comparative Survey of Medical Oncologists and Urologists

Urology Practice(2024)10.1097/upj.0000000000000740

N/A

0DataRank · unranked

5 citations

Andrew J. Armstrong, Eamonn Rogers, Dany Habr, Jochen Walz, Martin Gleave +9 more

HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101644

N/A

0DataRank · unranked

8 citations

Arun Azad, Mona Patel, Jason W.D. Hearn, Michele Wozniak, Fabian Zohren +5 more

Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry

Prostate Cancer and Prostatic Diseases(2021)10.1038/s41391-021-00460-y

N/A

0DataRank · unranked

4 citations

Wen-Chi Foo, Tyler A. Allen, Jason A. Somarelli, Kathryn E. Ware, Santosh Gupta +19 more

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

European Urology Open Science(2021)10.1016/j.euros.2021.09.015

N/A

0DataRank · unranked

19 citations

Emmanuel S. Antonarakis, Tina Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan +22 more

Intensification of Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer

Advances in Oncology(2024)10.1016/j.yao.2023.12.006

N/A

0DataRank · unranked

1 citations

Joseph J. Park, Andrew J. Armstrong, Jeffrey Shevach

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-001792

N/A

0DataRank · unranked

115 citations

Matthew D. Tucker, Ramy Sedhom, Eric Schwartz, Jason Zhu, Chester Kao +12 more

Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels

Nature Communications(2025)10.1038/s41467-025-64153-z

N/A

0DataRank · unranked

8 citations

Marina N. Sharifi, Jamie M. Sperger, Matthew R. Chrostek, Matthew L. Bootsma, Shannon R. Reese +22 more

AR-V7 and prediction of benefit with taxane therapy: Final analysis of PROPHECY.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.184

N/A

0DataRank · unranked

1 citations

Jun Luo, Monika Anand, Emmanuel S. Antonarakis, David M. Nanus, Paraskevi Giannakakou +10 more

Integrating systemic therapy and metastasis-directed therapy in oligometastatic hormone-sensitive prostate cancer

Prostate Cancer and Prostatic Diseases(2025)10.1038/s41391-025-01041-z

N/A

0DataRank · unranked

2 citations

Jarey H. Wang, Brian F. Chapin, Ana M. Aparicio, Sumit K. Subudhi, Phuoc T. Tran +9 more

Genetic ancestry concordant RNA splicing in prostate cancer involves oncogenic genes and associates with recurrence

npj Precision Oncology(2025)10.1038/s41698-025-00817-9

N/A

0DataRank · unranked

2 citations

Wen-Chi Foo, Lauren E. Howard, Shannon McGue, Bonnie LaCroix, Julie J.G. Kephart +19 more

Racial differences in organic anion transport proteins (OATP) and outcome in castration resistant prostate cancer treated with AR pathway inhibitors in Alliance A031201: A phase III trial.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.5_suppl.246

N/A

0DataRank · unranked

0 citations

Hyotae Kim, Michael J. Morris, Mohammad Alyamani, Roberto Diaz, Himisha Beltran +4 more

A memory-driven reinforcement learning model of phenotypic adaptation for anticipating therapeutic resistance in prostate cancer

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.11.03.686133

N/A

0DataRank · unranked

0 citations

Shibjyoti Debnath, Pelumi Olawuni, Andrew J. Armstrong, Jason A. Somarelli, Jason T. George +1 more

File S5 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

10.1158/1541-7786.22527263.v1

Top 100%

0DataRank

Top 100%0 citations

Susan Halabi, Gabor Kemeny, Monika Anand, Paraskevi Giannakakou, David M. Nanus +4 more

Convergent evolution of p38/MAPK activation in hormone resistant prostate cancer mediates pro-survival, immune evasive, and metastatic phenotypes

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.04.22.050385

N/A

0DataRank · unranked

14 citations

Santosh Gupta, Jared Eng, Gabor Kemeny, Bhairavy Puviindran, Wen‐Chi Foo +18 more

DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.129

N/A

0DataRank · unranked

0 citations

Richard E. Green, Joseph J. Park, Olesia Kellezi, Clara Hwang, Pedro C. Barata +15 more

RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis

Journal of Clinical Investigation(2023)10.1172/jci166647

N/A

0DataRank · unranked

106 citations

Jiaqi Chen, Yi Lu, Alyssa Bawcom, Jinjin Wu, Jianhong Ou +8 more

Fragmentomic analysis of circulating tumor DNA-targeted cancer panels

Annals of Oncology(2023)10.1016/j.annonc.2023.06.001

N/A

0DataRank · unranked

67 citations

Marina N. Sharifi, Jamie M. Sperger, Yue Shi, Matti Annala, Matthew L. Bootsma +29 more

Andrew J. Armstrong

Indexed papers

Top data-sharing exemplar

Papers